Stay away from Ranbaxy: Baliga

Published on Thu, Sep 04, 2008 at 10:23 |  Source : CNBC-TV18

Updated at Thu, Sep 04, 2008 at 13:44  

54216 Investors following Ranbaxy Labs. Share this News with them.
0
0
Share on Tumblr
Ambareesh Baliga, ., Karvy Stock Broking

Excerpts from Bazaar on CNBC-TV18 Watch the full show ยป

RELATED NEWS

ALSO READ

Ambareesh Baliga of Karvy Stock Broking is of the opinion that one should stay away Ranbaxy Laboratories .

Baliga told CNBC-TV18, "For the time being I would say stay away from Ranbaxy because we see it going more towards the levels of Rs 400, so closer to Rs 400 or Rs 410, it makes sense in investing in this company for slightly longer term perspective. For the time being one should ignore it because clearly post this open offer, the price should go down to levels of Rs 400 to Rs 410."

Disclosure: It is safe to assume that analyst and his client may have an investment interest in the above stock/sector.

  

More on Moneycontrol

Trending News

Business News

Logitech ZAAG iPad2 Keyboard Case
Competition ahoy: Monkey 1, Sensex in neck-and-neck race "Competition ahoy: Monkey 1, Sensex in neck-and-neck race"

Sources Say BCCI Sahara Meet BCCI Agrees To All Other Demands Put In By Sahara

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 12 2012, 11:20

See more rally even if Greek crisis drags on: RBS

- in FII View

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 12 2012, 15:00 | Source: CNBC-TV18

Bosch sees 3-5% growth in 2012, bets big on India  

Feb 11 2012, 11:52 | Source: CNBC-TV18

TCS to expand centers in N.America; CY12 focus on Japan  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com